ORIGINAL ARTICLE

Bali Medical Journal (Bali Med J) 2018, Volume 7, Number 1: 114-119
P-ISSN.2089-1180, E-ISSN.2302-2914

Aging changes’ inhibition of hemostasis and blood rheological features on the background of antioxidant liposomal preparation “Lipovitam-Beta” application

Makurina O.N.,1 Zaitsev V.V.,2* Kolesnikov A.V.,3 Sokol O.V.,3 Sadykhova A.V.3

ABSTRACT

Background: One of geroprotectors for mammals are still polyvitaminic preparatons, one of which is Lipovitam-beta. Purpose of research: to estimate Lipovitam-beta impact on the indices of hemostasis and blood rheology systems of aging rats.

Methods: We examined 193 healthy outbred male-rats at the age of 24 months being kept in conditions of vivarium and having traditional ration. In experimental group (98 rats) we investigated the impact of Lipovitam-beta feeding on the basis of 5.5 mg on 100 gr of body mass once in 5 days during 6 months on relevant indices. Control group was composed of 95 healthy male-rats. We estimated the basic indices of hemostasis, blood viscosity, aggregation and deformability of erythrocytes at the beginning and in 6 months of investigation.

Results: Lipovitam-beta application has led in case of rats from experimental group to reliable lowering of spontaneous and stimulated platelets’ aggregation and activity weakening of plasma hemostasis. On the background of Lipovitam-beta feeding to rats we found lowering of blood viscosity and erythrocytes’ aggregation index what was accompanied by increase of erythrocytes’ deformability index.

Conclusion: Application of Lipovitam-beta to aging rats led to activity lowering of plasma hemostasis and platelets, improving rheological features what can positively influence microcirculation, the level of vital activity and forthcoming life duration.

Keywords: rats, lactation, Lipovitam-beta, hemocoagulation, platelets, blood rheology

Cite This Article: Makurina, O.N., Zaitsev, V.V., Kolesnikov, A.V., Sokol, O.V., Sadykhova, A.V. 2018. Aging changes’ inhibition of hemostasis and blood rheological features on the background of antioxidant liposomal preparation “Lipovitam-Beta” application. Bali Medical Journal 7(1): 114-119. DOI: 10.15562/bmj.v7i1.626

INTRODUCTION

A living organism while its ontogenesis is in constant interaction with environment which including food composition, can influence its state defining the course of many physiological processes.1,2 Aging processes affect all levels of a living being’s organization negatively, influencing the structure and functions of the whole organism.3 Gradual wilting inevitably causes increase of different pathologic burden, lowering vital activity and advancing lethal outcome.4 Gradually, science comes to understand the great significance for mammals’ vital activity provision to the state of one of its integrating systems, which is blood.5

Its hemostatic and rheological features mostly define the degree of tissues’ perfusion and, consequently, anabolism level in an animal’s organism and its characteristics at any age.6 Because of great physiological significance and vulnerability of hemostasis and blood rheology, they are started to be investigated more and more actively.7

One of the valid ways causing intensification of anabolic processes in an organism and, thereby, increase of phenotypic manifestation of genetically conditional features8,9 is the application of different biologically significant impacts10,11 and biologically active substances.12 In their number, we include the rise of physical activity13 and also application of vitamins. The need for some vitamins in the case of mammals is very high and with the help of ration can’t sometimes be covered entirely.1 One of modern vitamin sources for laboratory mammals is Lipovitam-beta which, being made on the basis of liposomes, can provide maximum vitamins’ assimilation by an organism’s cells.14

It is known that blood is the most labile indicator of an organism’s state quickly reacting on different ingredients’ inflow.15,16 The more metabolism in an organism increases under their impact, the more evident will change in the blood.17,18 Besides, blood changing its composition, hemostatic and rheological features, can itself influence the functional state of the whole organism.19,20 In this connection we considered to be approved to fulfill estimation of Lipovitam-beta impact in case of aging laboratory rats on physiologically significant indices of hemostasis and blood rheology.
The aim of this study is to estimate Lipovitam-beta impact on the indices of hemostasis system and blood rheology of aging rats.

MATERIALS AND METHODS

Research was conducted in a strict manner according to ethical principles established by the European Convent on protection of the vertebrate used for experimental and other scientific purposes (adopted in Strasbourg March 18, 1986, and confirmed in Strasbourg June 15, 2006) and approved by the local ethic committee of Federal State Budgetary Educational Institution of Higher Education “Samara State Agricultural Academy” (Record № 11, dated December 4, 2015) and the local ethic committee of Samara National Research University (Record № 12 dated December 3, 2015).

This study involved a total of 193 healthy outbred male-rats of 24 months of age being kept in conditions of specially equipped for rats’ keeping vivarium. All the animals were healthy during the time preceded the moment of taking them into the investigation. The animals were casually subdivided into experimental and control groups. The experimental group was composed of 98 rats having additionally received Lipovitam-beta (“Biodom”, Russia) on the basis of 5.5 mg on 100 gram of an animal’s body mass by its solution in water forcibly being given to drink. The preparation was given twice in seven days during six months of investigation. Control group was composed of 95 male-rats of the same age being kept in the same conditions and receiving the same ration. The examination of animals in both groups was conducted twice, at the beginning and in six months of investigation (at the age of 30 months).

All the rats were examined with the object to the content of fibrinogen in blood by Klause’ modified method. Estimation of plasminogen level was defined by a kinetic method with the help of the device FP-901 (“LabSystems”, Finland) with chromogen substrates (“Dade Behring”, Germany). The concentration of soluble fibrin-monomeric complexes (SFMC) was defined by a visual method with the help of reagents by the firm “Technology-standard”, Russia. Activated partial thromboplastin time (APTT) was examined with the help of coagulometer “HumaClot” (“HUMAN GmbH”, Germany) with a set of reagents HemoStat aPTT-EL. The measurement of international normalized relation (INR) was made by Quick’s method. Platelets’ aggregative ability was examined with the help of two-channel laser analyzer of platelets’ aggregation (“Biola”, Russia) by the turbo-dymetric method. As inductor, we applied 0.5mkM ADP.

Registration of blood viscosity was fulfilled by rotary viscosimeter AKP-2 (“Melt”, Russia) at shift speeds 200 sec⁻¹ and 20 sec⁻¹ with the consequent calculation of erythrocytes’ aggregation index and deformability index. Statistical processing of the received results was made with the help of Student’s t-criterion. Statistical processing of received information was made with the help of a programme package “Statistics for Windows v. 6.0”, “MicrosoftExcel”. Differences in data were considered reliable in case of p<0.05.

RESULTS

Estimation of hemostasis state on in the end of both groups rats didn’t find significant differences in values of defined indices of coagulant and anticoagulative systems (table 1). Platelets’ functional activity before the start of investigation also had no differences in both groups.

At the beginning of the investigation, we also didn’t find any significant differences between both groups of animals as far as indices of blood rheological features are concerned. Blood viscosity at shift speed 200 sec⁻¹ in the group which later began to receive Lipovitam-beta was 4.20 ± 0.12 centipoise, while in the control group was 4.22 ± 0.17 centipoise. At shift speed 20 sec⁻¹ the values of blood viscosity were also comparable composing 6.34 ± 0.34 and 6.29 ± 0.32 centipoise, respectively. Initially indices’ values of erythrocytes’ deformability and erythrocytes’ aggregation of animals in both groups statistically didn’t differ from each other.

To the end of the study period, the rats receiving Lipovitam-beta were noted to have significant inhibition of APTT, the tendency for increase of INR and plasminogen indices, decrease of fibrinogen and SFMC concentrations. In the control group of rats in 6 months of the study, we noticed decrease of APTT, the tendency for decrease of INR and plasminogen activity, and increase of fibrinogen and SFMC.

After six months of investigation, rats from experimental group were noted to have a decrease of platelets’ aggregation (spontaneous on 10.6% and stimulated on 11.1%). In the control group of aging rats, spontaneous and ADP-induced platelets’ aggregation significant reliably increased, having exceeded initial values on 11.7% and 30.0%, respectively. At the same time, differences in platelets’ aggregation in both groups to the end of investigation composed for spontaneous – 22.9% (p<0.01), for stimulated – 43.7% (p<0.01).

At repeated investigation of accountable indices of blood rheological features in 6 months, we noticed multidirectional tendency of blood
viscosity common for animals of both groups. The rats from experimental group were noted to have the tendency to decrease of blood viscosity at shift speeds 20 sec$^{-1}$ and 200 sec$^{-1}$ on 8.4% and 4.3%, respectively. However, indices in control group showed a tendency to grow on 5.7% and 6.9% for blood viscosity at shift speeds of 200 sec$^{-1}$ and 20 sec$^{-1}$, correspondingly. Experimental rats were also noted to have a tendency to value decrease of erythrocytes' aggregation index by 4.0%, while control animals were found to have a tendency to increase by 5.5%. At the same time index of erythrocytes' deformability of aging rats having received Lipovitam-beta had a tendency to increase and in the case of control animals had a tendency to decrease.

**DISCUSSION**

Being clear genetically coded all the features of a living organism\textsuperscript{23,24} can change the degree of their phenotypic survival depending on the environment.\textsuperscript{25} In this connection, high urgency of profound investigation continuation of living organisms’ physiology different aspects\textsuperscript{26} and a human being is still kept, including negative environmental conditions\textsuperscript{27,28} with obligatory registration of their social consequences.\textsuperscript{29} In this connection, additional investigations devoted to mammals physiology can provide solid basis for further perfection of impedes the aging technologies.\textsuperscript{1,3} As the result of summation of received during these investigations knowledge and their consequent practical application we can reach medical progress.\textsuperscript{2,5} In previous investigations they showed with the help of different biological objects that hemostasis\textsuperscript{30,31} and hemorheology\textsuperscript{32,33} rather keenly respond to environmental impacts including unfavorable factors\textsuperscript{34} and development of different dysfunctions\textsuperscript{35} and evident pathology\textsuperscript{15,16} in an organism. It is also known that inhibition of lipid peroxidation and suppression of lack of vitamins can influence a living organism rather variously and favorably.\textsuperscript{38} It was noted that on this background activity decrease of many components of hemostasis system\textsuperscript{39} and improvement of blood rheological parameters on the whole and erythrocytes in particular\textsuperscript{40,41} are developing. With these very changes of hematological indices, we connect improvement of microcirculation processes and intensification of metabolic processes on the background of different varients’ impacts on an organism having in its basis antioxidant impact.\textsuperscript{42} As the result of fulfilled investigation on the background of Lipovitam-beta application, the aging rats were noted to have a weakening of hemocoagulation along both ways of its realization.\textsuperscript{21} It is evidently connected with decrease of most coagulation factors participating in it. Most probably that some decrease of
thromboplastin generation and weakening of XII factor’s contact activation were also developing in these animals’ blood. Lipovitam-beta addition into animals’ feeding also led to decrease of fibrinogen and SFMC in blood what pointed at inhibition of its polymerization which was actively restrained by a physiologically activated system of fibrinolysis. Control aging rats were noted to have opposite phenomena promoting the increase of all the hemocoagulation stages and decrease of fibrinolysis activity.

Relying on literature data we can consider that Lipovitam-beta application stimulates organism’s antioxidant protection,\(^{55,56}\) what, as it is known, decreases platelets’ ability to both spontaneous and stimulated aggregation.\(^{57,58}\) We have some basis to think that addition of the given preparation into animals’ feeding rises their level of cyclic adenosine monophosphate in platelets and decreases thromboxane A\(_2\) formation. Given situation blocks the formation of thrombocyte aggregates in the lumen of the vascular bed.\(^{59,60}\) Noted in control rats aptitude to the growth of platelets’ aggregative ability may be connected with the decrease of cyclic adenosine monophosphate\(^{61}\) and increase of thromboxane A\(_2\) synthesis in them,\(^{62,63}\) naturally leading to increase of platelets’ dynamic aggregates’ number in these animals’ blood.\(^{64,65,66}\)

The increase of erythrocytes’ aggregation which found in control rats can mostly be provided by coming changes of their membranes’ charge because of degradation on their surface of some glycoproteins under the influence of always strengthening in conditions of low physical activity lipid peroxidation.\(^{67}\) Intensification of oxygen active forms’ generation in given conditions provides oxidative alteration of erythrocyte membranes’ structures in these animals\(^{68}\) at simultaneous damage of plasma globular proteins having the ability to be connected in the kind of “bridges” between erythrocytes and realize their aggregation.\(^{69}\) Given situation promotes the growth of disaggregation threshold of control rats red platelets.\(^{70}\)

It can be hypothesized that weakening of erythrocytes’ aggregation which found in experimental rats is mostly provided by strengthening of antioxidant plasma activity as the result of Lipovitam-beta application. On this background we noticed decrease of \(\alpha_2\)-receptors activity, weakening of \(\text{Ca}^{2+}\)-calmodulin system and cascade of phosphatidylinositol intracellular reactions.\(^{71}\) ‘Taking place at this time decrease of \(\alpha_2\)-adrenoreceptors’ activity leads to strengthening of adenylate cyclase during physiological impacts from receptors on Gi-proteins what causes rise of cyclic adenosine monophosphate quantity in erythrocytes, blocks \(\text{Ca}^{2+}\) inflow into them, providing not high erythrocytes’ aggregation.\(^{72,73}\)

We can consider that erythrocytes of animals having received Lipovitam-beta are more able to deformation what is an important factor of maintenance in them of necessary microcirculatory bed’s perfusion. It is possible that in these animals’ erythrocytes there is the rise of ATP content what positively influences the interaction of spectrin, actin and other integral proteins of the erythrocyte membrane playing an important role in its features’ maintenance. Besides, the rise of erythrocytes’ deformability in experimental rats is mostly explained by lowering of unbounded ions \(\text{Ca}^{2+}\) concentration what minimizes its interaction with membrane’s proteins and makes it more deformed. At the same time, in erythrocytes of control animals, there is evidently lowering of ATP content what negatively changes the character of interaction of spectrin, actin and erythrocyte membrane’s integral proteins. Erythrocytes’ deformability lowering in control cows is evidently mostly caused by the rise of unbounded ions \(\text{Ca}^{2+}\) level in them which interacting with membrane’s proteins make it firmer and less deformed.\(^{74}\)

In modern literature, the opinion is gradually forming about close connection of somatic status capacity with their hematological indices.\(^{75,76}\) At the same time, in this investigation, we didn’t trace the whole lactation and, that’s why it’s too early to make conclusions about the impact of Lipovitam-beta feeding on degree aging trying to explain the results from the position of hemostasis activity dynamics and state of blood rheology.

CONCLUSION

From senescent rats older than two years get the tendency to hemostasis activation and worsening of blood rheological features which negatively influences microcirculation and can become one of the factors gradually limiting viability. Lipovitam-beta application to aging rats led to decrease of plasma hemostasis and platelets’ functional activity, weakening of erythrocytes’ aggregative ability, strengthening of their deformability, improvement of blood fluidity at different shift speeds what can positively influence microcirculation and level of dairy anabolism.

CONFLICT OF INTEREST

No conflict of interest to declare.
REFERENCES

1. Vatnikov YuA, Zavalishina SYu, Kulikov EV, Vilkovskiy IF, Nikishov AA, Drukovsky SG, Krotova EA, Khomenets NG, Bolskhova M.Y. 2017. Correctional abilities of regular muscle activity in relation to erythrocytes’ microhematological features of rats with experimentally developed hypertension. Bali Medical Journal. 2017;6(4):449–456. doi:10.15562/bmj.v6i3.856.

2. Medvedev IN, Amelina IV. Ag polymorphism as a cytogenetic maker of arterial hypertension risk. Russian Journal of Cardiology. 2009;2(76):70–72.

3. Medvedev IN, Gromnatskii NI. Correction of thrombocyte hemostasis and biological age reduction in metabolic syndrome. Klinicheskaia meditsina.2005;83(8):54–57.

4. Simonenko VB, Medvedev IN, Kumova TA. Losartan for correction of thrombocyte activity in patients suffering from arterial hypertension with metabolic syndrome. Klinicheskaia meditsina.2008;86(1):38–41.

5. Medvedev IN, Kumova TA. Comparison of platelet hemostasis effects for angiotensin receptor blockers in patients with arterial hypertension and metabolic syndrome. Russian Journal of Cardiology.2007;4:52–56.

6. Medvedev IN, Vatnikov YuA, Vosova TYu. Verospiron effects on platelet aggregation in patients with arterial hyper tension and abdominal obesity. Russian Journal of Cardiology.2007;6:55–58.

7. Medvedev IN, Mezentseva IN, Tsholmachev VV. ACE inhibitors potential in correcting vessel wall anti-aggregation activity among patients with arterial hypertension and metabolic syndrome. Russian Journal of Cardiology.2007;1:48–52.

8. Amelina IV, Medvedev IN. Transcriptional activity of chromosome nuclear organizing regions in population of Kursk region. Bulletin of Experimental Biology and Medicine.2009;147(6):730–732.

9. Amelina IV, Medvedev IN. Evaluation of the dependence of mutagenesis intensity on activity of nucleolus organizer regions of chromosomes in aboriginal population of Kursk region. Bulletin of Experimental Biology and Medicine.2008;145(1):68–71.

10. Medvedev IN. Platelet functional activity in rats, prolonged experiencing regular exercise. Vestnik SPbSU. Series 3. Biology. 2016;6:99–107. DOI: 10.21638/11701/spbu03.2016.407.

11. Zavalishina SYu, Vatnikov YuA, Kulikov EV, Yanikov SA, Karamyan AS, Sturov NV, Byakhova VM, Kochneva MV, Petryaeva AV. Diagnostics of erythrocytes’ microrheological features and early abnormalities of rats in the model of experimental hypertension development. Bali Medical Journal. 2017;6(3):470–475. doi: 10.15562/bmj.v6i3.589.

12. Medvedev IN, Danilenko OA. Comparative effects of therapeutic complexes on vascular wall activity in patients with arterial hypertension, metabolic syndrome, and recent ocular vessel occlusion. Cardiovascular therapy and prevention.2010;9(7):27–32.

13. Medvedev IN, Savchenko AP. Platelet activity correction by regular physical training in young people with high normal blood pressure. Russian Journal of Cardiology.2010;2(82):35–38.

14. Vosova T Yu, Ulitko VE, Lifarova SP. Morphobiocchemical composition of cows blood as criterion of bioactivity of preparation Lipovitam-beta. Zootechniya. 2013;8:2–3.

15. Simonenko VB, Medvedev IN, Kumova TA. Effect of eprosartan on thrombocytes aggregative capacity in patients with arterial hypertension and metabolic syndrome. Klinicheskaia meditsina.2008;86(4):19–21.

16. Medvedev IN, Gromnatskii NI, Volobuev IV, Dement’ev VI, Storozhenko MV. Thrombocytic hemostasis in hypertensive patients with metabolic syndrome and its correction with lovastatin. Klinicheskaia meditsina.2004;82(10):37-41.

17. Medvedev IN, Lapshina EV, Zavalishina SYu. Activity of platelet hemostasis in children with spinal deformities. Bulletin of experimental biology and medicine.2010;149(3):645–646.

18. Medvedev IN. A comparative analysis of normodipin and spirapril on intravascular activity of platelets in patients with metabolic syndrome. Terapevticheskii Arkhim. 2007;79(10):25–27.

19. Medvedev IN, Kumova TA. Valsartan effects on platelet activity in patients with arterial hypertension and metabolic syndrome. Russian Journal of Cardiology.2007;3:66–69.

20. Simonenko VB, Medvedev IN, Tsholmachev VV. Pathogenetic aspects of arterial hypertension in metabolic syndrome Klinicheskaia meditsina.2011;89(1):49–51.

21. Barkazan ZS, Morot AP. Diagnosis and therapy controlled hemostasis disorders. Moscow: N’judjamed, 2008: 292.

22. Medvedev IN, Savchenko AP, Zavalishina SYu, Krasnova EG, Kumova TA, Gamolina OV, Skoryatina IA, Fadeeva TS. Methodological approaches to the study of the rheological properties of blood in various states. Russian Journal of Cardiology.2009:5:42–45.

23. Medvedev IN, Amelina IV. An association between human morphological phenotypical characteristics and the activity of chromosomal nucleolar organizer regions in the interphase cell nucleus in the population of indigenous people of Kursk region. Morphology. 2012;142(4):87–91.

24. Amelina IV, Medvedev IN. Relationship between the chromosome nucleoli-forming regions and somatometric parameters in humans. Bulletin of Experimental Biology and Medicine. 2009;147(1):77–80.

25. Kutafina NV, Medvedev IN. Platelet aggregation clinically healthy persons of the second coming of age living in the Kursk region. Advances in gerontology = Uspekhi gerontologii /Rossiiskaia akademiia nauk, Gerontologicheskoe otsenki, 2015;28(2):321–325.

26. Vatnikov YuA, Zavalishina SYu, Plushchikhov VG, Kuznetsov VI, Selezniev SB, Kubatbekov TS, Rystsova EO, Parshina VI. Early-changes diagnostics of erythrocytes microhematological features in the model of dyslipidemia development in rats at the late stages of ontogenesis. Bali Medical Journal (Bali Med J) 2017, Volume 6, Number 1: 216–222. DOI: 10.15562/bmj.v6i1.483.

27. Medvedev IN, Gromnatskii NI, Golikov BM, At-Zurakii EM, Li VI. Effects of lisinopril on platelet aggregation in patients with arterial hypertension with metabolic syndrome. Kardiologiya.2004;44(10):57–59.

28. Simonenko VB, Medvedev IN, Kumova TA. Pathogenetic aspects of arterial hypertension in case of metabolic syndrome. Voeno-meditsinski zhurnal. 2010;331(9):41–44.

29. Medvedev IN, Amelina IV. Evaluation of the relationship between chromosome aberrations and transcription activity of nucleolus organizer regions in indigenous Population of the Kursk Region. Bulletin of Experimental Biology and Medicine. 2010;149(3):332–336.

30. Medvedev IN, Skoryatina IA. Effect of lowfat on adhesive and aggregative function of platelets in patients with arterial hypertension and dyslipidemia. Klinicheskaia meditsina.2010;88(2):38–40.

31. Medvedev IN, Gromnatskii NI. The influence of nebivolol on thrombocyte aggregation in patients with a trial hypertension with metabolic syndrome. Klinicheskaia meditsina.2005;83(3):31–33.

32. Simonenko VB, Medvedev IN, Kumova TA. Effect of eprosartan on thrombocytes aggregative capacity in patients with arterial hypertension and metabolic syndrome. Klinicheskaia meditsina.2008;86(4):19–21.

33. Medvedev IN, Skoryatina IA. Dynamics of microhematological properties of erythrocytes in patients with arterial hypertension and dyslipidemia treated with atorvastatin. Klinicheskaia meditsina.2012;90(6):42–45.

34. Medvedev IN. Dynamics of violations of intravascular platelet activity in rats during the formation of metabolic syndrome using fructose models. Problems of nutrition.2016; 85(1):42–46.
35. Medvedev IN. Correction of primary hemostasis in patients suffering from arterial hypertension with metabolic syndrome. Klinicheskaia meditsina. 2007; 85(3):29–33.
36. Simonenko VB, Medvedev IN, Tolmachev VV. Effect of irbesartan on the function of hemocogulative component of hemostasis in patients with arterial hypertension during metabolic syndrome. Klinicheskaia meditsina.2010;88(6):27–30.
37. Medvedev IN, Zavalishina SYu. Platelet Activity in Patients With Third Degree Arterial Hypertension and Metabolic Syndrome. Kardiologiya. 2016;56(1):48.
38. Simonenko VB, Medvedev IN, Kumova TA. Losartan for correction of thrombocyte activity in patients suffering from arterial hypertension with metabolic syndrome. Klinicheskaia meditsina. 2008;86(1):38–41.
39. Gromnatskii NI, Medvedev IN. Non-pharmacological correction of impaired platelet hemostasis in hypertensive patients with metabolic syndrome. Klinicheskaia meditsina. 2003;81(4):31–34.
40. Medvedev IN, Skoriatina IA. Erythrocyte aggregation in patients with arterial hypertension and dyslipidemia treated with pravastatin. Klinicheskaia meditsina.2014;92(11):34–38.
41. Medvedev IN, Kumova TA. Angioteins II receptor inhibitors: role and place in arterial hypertension and metabolic syndrome treatment. Russian Journal of Cardiology. 2007;5:97–99.
42. Medvedev IN, Danilenko OA. Complex correction of vascular hemostasis in patients with arterial hypertension, metabolic syndrome, and recent ocular vessel occlusion. Russian Journal of Cardiology.2010;4(84):15–19.
43. Simonenko VB, Medvedev IN, Mezentseva NI, Tolmachev VV. The antiaggregation activity of the vascular wall in patients suffering from arterial hypertension with metabolic syndrome. Klinicheskaia meditsina. 2007;85(7):28–30.
44. Medvedev IN, Gromnatskii NI. The influence of hypocaloric diet on thrombocyte rheology in patients with metabolic syndrome. Klinicheskaia meditsina.2006;84(3):49–52.
45. Medvedev IN, Danilenko OA. Effectiveness of vascular wall activity correction in patients with arterial hypertension, metabolic syndrome, and oculo-vascular occlusion. Russian Journal of Cardiology. 2010;3(83):64–67.
46. Simonenko VB, Medvedev IN, Tolmachev VV. Comparative evaluation of the influence of sulphhydril and phosphate ACE inhibitors on thrombocyte aggregation in patients suffering from arterial hypertension with metabolic syndrome. Klinicheskaia meditsina. 2007;85(4):24–27.
47. Medvedev IN, Skoriatina IA. Platelet hemostasis dynamics in simvastatin- treated patients with arterial hypertension and dyslipidemia. Russian Journal of Cardiology,2010;1(81):54–58.
48. Medvedev IN, Gromnatskii NI. Effect of amlodipine on intravascular thrombocyte activity in patients with arterial hypertension and metabolic syndrome. Klinicheskaia meditsina. 2006;83(2):37–39.
49. Medvedev IN, Gromnatskii NI, Mohamed A-ZE. Comparative Assessment of Effects of Qadropril and Enalapril on Intravascular Activity of Platelets in Hypertensive Patients With Metabolic Syndrome. Kardiologiya. 2004;44(12):44–46.
50. Simonenko VB, Medvedev IN, Gamolina OV. Primary hemostasis activity in patients with arterial hypertension and impaired glucose tolerance treated with trandolapril. Klinicheskaia meditsina.2011;89(2):29–31.
51. Simonenko VB, Medvedev IN, Tolmachev VV. Dynamics of primary hemostasis activity in patients with arterial hypertension and metabolic syndrome treated with candesartan. Klinicheskaia meditsina. 2011;89(3):35–38.
52. Simonenko VB, Medvedev IN, Briukhovetskii AG. Effect of therapy with diuretics on the functional activity of platelets in patients with arterial hypertension and abdominal obesity. Klinicheskaia meditsina. 2012;90(11):54–56.
53. Skoriatina IA, Zavalishina SYu. Ability to aggregation of basic regular blood elements of patients with hypertension and dyslipidemia receiving non-medication and simvastatin. Bali Medical Journal. 2017;6(3):514–520. doi:10.15562/bmj.v6i3.552
54. Kotova OV, Zavalishina SYu, Makurina ON, Kiperman YaV, Savchenko AP, Skoblikova TV, Skripleva EV, Zacepin VI, Skripleva AV, Andreeva VYu. Impact estimation of long regular exercise on hemostasis and blood rheological features of patients with incipient hypertension. Bali Medical Journal. 2017;6(3):514–520. doi:10.15562/bmj.v6i3.552
55. Medvedev IN, Kumova TA. Reduced platelet aggregation in losartan-treated patients with arterial hypertension and metabolic syndrome. Russian Journal of Cardiology. 2006;5:53–55.
56. Medvedev IN, Kumova TA, Gamolina OV. Renin-angiotensin system role in arterial hypertension development. Russian Journal of Cardiology. 2009;4:82–84.
57. Medvedev IN, Skoriatina IA. Effect of lovastatin on adhesive and aggregation function of platelets in patients with arterial hypertension and dyslipidemia. Klinicheskaia meditsina. 2010;88(2):38–40.